Last updated: November 10, 2026
Cantharidin became a regulated prescription drug in the United States when the FDA approved YCANTH, a 0.7% topical solution, in July 2023. Verrica Pharmaceuticals owns and commercializes YCANTH for molluscum contagiosum in adults and children aged 2 years and older. The product converted a historically compounded treatment into an FDA-approved pharmaceutical category with defined manufacturing, labeling, and intellectual-property protection.
The commercial opportunity is concentrated in pediatric dermatology. Market adoption depends on physician familiarity, reimbursement, office-based administration, treatment capacity, and the ability of Verrica to displace compounded cantharidin and procedural treatments. YCANTH has no conventional biosimilar risk, but its long-term pricing power is exposed to generic or competing topical products after regulatory and patent protections expire.
What is cantharidin and what drug is FDA-approved?
Cantharidin is a vesicant derived from blister beetles. Applied topically, it produces a controlled blister that removes lesions after the treated area heals. It has been used by dermatologists for decades, but historically was generally obtained through compounding pharmacies rather than through an FDA-approved commercial product.
YCANTH is the first FDA-approved cantharidin product in the United States. Its approved indication is the topical treatment of molluscum contagiosum in adults and pediatric patients aged 2 years and older. The product is applied by a health-care professional using a single-use applicator and is removed after 24 hours. Treatment can be repeated every three weeks as needed [1].
| Attribute |
YCANTH |
| Active ingredient |
Cantharidin |
| Strength |
0.7% |
| Dosage form |
Topical solution |
| Sponsor |
Verrica Pharmaceuticals Inc. |
| FDA application |
NDA 214701 |
| Approval date |
July 21, 2023 |
| Indication |
Molluscum contagiosum |
| Patient population |
Adults and children aged 2 years and older |
| Administration |
Health-care professional application |
| Reimbursement model |
Prescription product, primarily office-based dermatology |
| Main historical alternative |
Compounded cantharidin |
The FDA approval established a defined commercial pathway for cantharidin but did not eliminate off-label treatment alternatives. Dermatologists may still use cryotherapy, curettage, observation, and other off-label therapies.
How large is the U.S. cantharidin market?
The commercial market is an office-based dermatology opportunity rather than a traditional retail-prescription market. Molluscum contagiosum is common in children, but many cases resolve spontaneously. That natural-history profile limits treatment penetration and gives parents and clinicians a reason to defer intervention.
The addressable market has four principal segments:
- Pediatric patients with numerous or persistent lesions.
- Patients with lesions in visible, sensitive, or high-friction areas.
- Patients whose families prefer active treatment over observation.
- Patients treated in dermatology, pediatric, or primary-care offices that can administer YCANTH.
Verrica has cited an estimated U.S. molluscum contagiosum population of millions of patients annually, with a substantial portion receiving medical care. The practical revenue opportunity is smaller than the epidemiological population because many patients are untreated, self-resolve, or receive low-cost procedures.
What drives YCANTH demand?
Demand is determined by:
- Physician recognition of FDA-approved cantharidin as a standardized option.
- Access to pediatric dermatologists and dermatology clinics.
- Payer coverage and patient out-of-pocket costs.
- Number of lesions treated per visit.
- Repeat-application frequency.
- Office workflow and reimbursement for treatment administration.
- Availability and price of compounded cantharidin.
- Parent preference for active lesion removal.
The product’s office-administered model can increase revenue per patient compared with a conventional pharmacy prescription, but it also creates operational friction. Clinics must stock the product, train staff, document application, manage blistering, and address caregiver expectations.
What is the financial trajectory for YCANTH and Verrica?
YCANTH is the central commercial asset in Verrica’s portfolio. The company began commercializing the product after approval in 2023 and has reported early revenue growth from a low base. Public filings indicate that Verrica remains a development-stage or commercialization-stage company with continuing operating losses and dependence on capital markets, product sales, and licensing transactions [2].
The financial trajectory follows a typical specialty-product pattern:
| Phase |
Financial condition |
Main commercial issue |
| 2023 launch |
Initial product revenue and high launch spending |
Build prescriber and distributor coverage |
| 2024 expansion |
Rising sales and broader account penetration |
Convert trial into repeat treatment |
| 2025-2027 scale-up |
Potential operating leverage if demand expands |
Improve reimbursement and payer access |
| Post-exclusivity period |
Greater price and volume pressure |
Defend formulation, manufacturing, and brand equity |
Revenue quality is more important than prescription count. YCANTH is applied in the office, and revenue depends on the number of treatment sessions, vial utilization, channel discounts, and reimbursement. Repeat treatment can increase revenue per patient, but spontaneous resolution and variable lesion burden make patient-level forecasting difficult.
Verrica’s cost structure includes:
- Sales representatives and dermatology promotion.
- Medical education and payer contracting.
- Manufacturing and quality-control costs.
- Distribution and specialty-pharmacy infrastructure.
- Research and development for additional indications.
- Legal and regulatory costs.
- Public-company overhead.
The main financial risk is a prolonged period in which commercial revenue grows but does not cover operating expenses. The company must reach sufficient scale before patent and regulatory protections weaken. Licensing transactions outside the United States could reduce commercialization costs but would also transfer a portion of product economics to regional partners.
What is the FDA exclusivity timeline for YCANTH?
YCANTH did not qualify for traditional five-year new chemical entity exclusivity because cantharidin is an established active ingredient. The product instead received FDA approval based on a new clinical formulation and delivery system supported by clinical studies.
The likely principal regulatory protection is three-year exclusivity for the approved formulation and indication based on new clinical investigations. That protection restricts approval of certain abbreviated applications relying on the same clinical investigations, but it does not create the same barrier as five-year NCE exclusivity [1,3].
| Regulatory event |
Date or expected period |
| FDA approval of YCANTH |
July 21, 2023 |
| Three-year clinical-investigation exclusivity |
Generally extends to July 2026 |
| Patent protection |
Extends beyond regulatory exclusivity, subject to listed patent scope and validity |
| Pediatric exclusivity |
No publicly established six-month pediatric extension identified for YCANTH |
| Orphan-drug exclusivity |
Not applicable to molluscum contagiosum |
The July 2026 regulatory milestone should not be treated as an automatic generic-launch date. Generic entry would depend on patent certifications, FDA review, litigation, settlement terms, and the commercial feasibility of reproducing the product’s single-use application system.
What patents protect YCANTH and cantharidin formulations?
YCANTH’s patent position is directed primarily to the formulation, delivery system, packaging, and methods of using topical cantharidin rather than to the active ingredient itself. Cantharidin is an old compound and cannot support broad composition-of-matter protection as a new chemical entity.
Publicly available FDA and patent records identify U.S. patents associated with YCANTH and its formulation technology. The relevant estate includes patents covering cantharidin compositions, topical application, and product characteristics. Exact Orange Book listing status should be checked against the current FDA publication because patent listings and delisting events can change.
| Protection layer |
Strategic purpose |
| Cantharidin formulation |
Controls concentration, excipients, stability, and product performance |
| Topical delivery system |
Supports uniform application and controlled exposure |
| Single-use applicator |
Limits dosing variability and cross-contamination |
| Method of treatment |
Protects treatment of molluscum lesions using the commercial formulation |
| Manufacturing controls |
Creates practical barriers to consistent pharmaceutical-grade production |
| Trade secrets |
Protects process parameters, testing, scale-up, and quality systems |
The central weakness is the absence of active-ingredient exclusivity. A competitor could seek approval for a different cantharidin formulation, strength, delivery vehicle, or indication without necessarily infringing every YCANTH claim.
What is the Orange Book status of YCANTH?
YCANTH is an FDA-approved prescription drug listed in the FDA’s Orange Book under NDA 214701. The Orange Book is the principal source for determining listed patents, expiration dates, and the availability of therapeutic-equivalence codes [3].
For commercial and litigation analysis, the relevant questions are:
- Which patents are listed against NDA 214701?
- What expiration dates appear in the current Orange Book?
- Do listed patents cover the approved product or only selected methods?
- Has any applicant submitted a Paragraph IV certification?
- Has Verrica filed suit within the statutory 45-day period?
- Has a court imposed a 30-month stay or entered an earlier judgment?
The Orange Book does not by itself guarantee exclusivity. A listed patent can be challenged for invalidity, non-infringement, or improper listing. Conversely, a patent not listed in the Orange Book may still support infringement claims in a separate action, although it may not generate the same automatic approval stay.
Are there Paragraph IV challenges or generic competitors?
No major public Paragraph IV challenge to YCANTH had been reported in the public record available through 2024. The absence of a disclosed challenge does not eliminate future risk. The first commercial opportunity for a generic applicant is likely to emerge as the three-year regulatory exclusivity period approaches expiration.
A generic applicant would face several technical issues:
- Demonstrating pharmaceutical equivalence to the approved formulation.
- Establishing stability for a vesicant topical product.
- Reproducing the single-use applicator and packaging.
- Matching concentration and excipient performance.
- Addressing application-site safety.
- Determining whether a full NDA, 505(b)(2) application, or abbreviated pathway is available.
- Resolving listed formulation and method-of-use patents.
A 505(b)(2) applicant could pursue a differentiated cantharidin product rather than a direct generic equivalent. That pathway might support a different concentration, vehicle, packaging configuration, or dosing method while relying partly on existing cantharidin safety information.
What competing treatments affect YCANTH?
YCANTH competes with both products and clinical procedures. The principal competitive alternatives are:
| Alternative |
Market position |
Competitive effect |
| Compounded cantharidin |
Familiar to dermatologists before YCANTH |
Directly competes on price and availability |
| Cryotherapy |
Established office procedure |
Competes on speed and physician familiarity |
| Curettage |
Effective lesion removal |
More invasive and operator-dependent |
| Observation |
Common for mild disease |
Reduces treatment demand |
| Imiquimod |
Used off-label in some settings |
Evidence and tolerability are variable |
| Berdazimer gel |
Investigational or emerging alternative |
Could provide an at-home prescription option |
| Other topical agents |
Limited or off-label use |
Fragmented competitive pressure |
Compounded cantharidin is the most direct competitor because it offers the same active ingredient and historical treatment concept. YCANTH’s advantages are FDA approval, standardized concentration, commercial supply, labeling, and quality controls. Its disadvantages include acquisition cost, reimbursement uncertainty, and the need for office application.
An at-home product could pose a greater commercial threat than another office-administered therapy because it would reduce clinic burden and potentially broaden access. Verrica’s ability to maintain physician preference will depend on treatment convenience, outcomes, safety, and net price.
Is there biosimilar risk for cantharidin?
There is no conventional biosimilar risk. Cantharidin is a small-molecule drug, not a biologic. Competitors would enter through generic, 505(b)(2), or full NDA pathways rather than through the biosimilar pathway established under the Public Health Service Act.
The relevant risk is formulation substitution. A competitor could develop a different topical cantharidin product that does not qualify as a therapeutically equivalent generic but competes clinically with YCANTH.
What manufacturing and intellectual-property barriers protect YCANTH?
Manufacturing-grade cantharidin must meet pharmaceutical standards for identity, potency, purity, stability, and contamination control. Historical compounded products do not necessarily provide a reliable benchmark for commercial-scale manufacturing.
The principal manufacturing barriers are:
- Consistent active-ingredient sourcing.
- Control of concentration in a vesicant formulation.
- Long-term stability.
- Container-closure compatibility.
- Single-use applicator production.
- Batch release testing.
- Quality-system compliance.
- Clinical reproducibility across treatment sites.
These barriers can delay competitors, but they are not equivalent to biologic manufacturing complexity. A well-capitalized generic or specialty pharmaceutical company could likely reproduce the product if the formulation and device claims are narrow or invalidated.
What licensing deals and geographic rights affect cantharidin?
Verrica has pursued regional commercialization and licensing opportunities for its dermatology portfolio. The economic importance of these arrangements depends on upfront payments, development milestones, royalties, minimum purchase commitments, and territorial control.
The United States remains the primary near-term market because YCANTH has FDA approval and a developed commercial infrastructure. International expansion requires separate regulatory submissions and may encounter different treatment standards, compounding practices, and reimbursement systems.
Geographic value is constrained by:
- Country-specific approval requirements.
- Existing physician use of compounded cantharidin.
- Different prevalence and treatment rates.
- Patent validity and enforceability.
- Local manufacturing or distribution requirements.
- Reimbursement for pediatric dermatology.
Licensing can reduce Verrica’s selling expenses but may lower gross economics and limit strategic control. A regional partner with established dermatology infrastructure could accelerate access in markets where Verrica lacks a commercial presence.
What generic launch scenarios exist for YCANTH?
Three scenarios are commercially plausible:
Earliest-entry scenario
A competitor challenges listed patents before or around the end of regulatory exclusivity. Verrica files patent litigation, triggering the statutory stay where applicable. Entry occurs only after settlement, patent invalidity, non-infringement, or expiration.
Delayed-entry scenario
The first applicant receives approval after the regulatory exclusivity period but remains blocked by valid formulation or method patents. Generic entry begins after patent expiry or a negotiated launch date.
Competitive reformulation scenario
A 505(b)(2) applicant launches a different cantharidin product that avoids key YCANTH claims. This product could enter before direct generic substitution and compete through a separate label, application device, or dosing regimen.
The most likely initial impact is price pressure in high-volume dermatology accounts rather than immediate displacement of the branded product across the entire market. Physician preference, reimbursement, and supply reliability will determine substitution rates.
How strong is the cantharidin patent estate?
The estate is commercially meaningful but narrower than the estate for a new molecular entity. Its strengths are the approved clinical use, proprietary formulation, standardized device, and manufacturing know-how. Its weaknesses are the old active ingredient, limited indication, relatively simple topical dosage form, and potential availability of alternative formulations.
| Factor |
Assessment |
| Active ingredient protection |
Weak or unavailable because cantharidin is old |
| Formulation protection |
Potentially meaningful |
| Device and packaging protection |
Potentially meaningful, depending on claim scope |
| Method-of-use protection |
Relevant to approved molluscum treatment |
| Regulatory exclusivity |
Limited compared with NCE products |
| Manufacturing barrier |
Moderate |
| Biosimilar barrier |
Not applicable |
| Generic substitution risk |
Moderate after exclusivity and patent challenges |
| Commercial moat |
Based on brand, physician adoption, supply, and reimbursement |
The financial value of the estate therefore depends on execution. Strong sales growth before 2026 would improve the return on the product, while weak adoption would leave less time to recover launch and development costs before competitive pressure increases.
Key Takeaways
- YCANTH is the first FDA-approved cantharidin product in the United States.
- Verrica’s opportunity is concentrated in pediatric and specialty dermatology.
- The product competes directly with compounded cantharidin, procedures, observation, and emerging topical therapies.
- Traditional five-year NCE exclusivity is not the principal protection because cantharidin is an established active ingredient.
- The key regulatory exclusivity period generally extends to July 2026.
- Patent protection focuses on formulation, application, packaging, methods of use, and manufacturing rather than the active ingredient.
- No conventional biosimilar pathway applies.
- No major public Paragraph IV challenge was identified through 2024.
- The principal financial risk is the need to scale revenue and payer access before regulatory and patent barriers weaken.
- Long-term value depends on repeat treatment, office adoption, reimbursement, international licensing, and the ability to defend the commercial formulation.
FAQs About Cantharidin and YCANTH
When will generic cantharidin be available?
Regulatory exclusivity is expected to limit certain competing approvals until approximately July 2026, but generic entry also depends on Orange Book patents, Paragraph IV litigation, settlements, and alternative 505(b)(2) products.
Is YCANTH the same as compounded cantharidin?
Both use cantharidin, but YCANTH is an FDA-approved, standardized pharmaceutical product with defined concentration, labeling, manufacturing controls, and a commercial applicator. Compounded products may differ in formulation, strength, packaging, and quality controls.
Can YCANTH be purchased for home use?
YCANTH is designed for application by a health-care professional. It is not an ordinary over-the-counter product, and its handling requires attention to the blistering effect and exposure precautions.
What company owns the cantharidin drug YCANTH?
Verrica Pharmaceuticals owns and commercializes YCANTH in the United States. Regional rights may be subject to licensing or partnership arrangements.
Does cantharidin have orphan-drug protection?
Molluscum contagiosum is not an orphan indication for YCANTH, and the product does not rely on orphan-drug exclusivity.
References
-
U.S. Food and Drug Administration. (2023). YCANTH (cantharidin) topical solution, 0.7%: Prescribing information. FDA.
-
Verrica Pharmaceuticals Inc. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, Form 10-K. U.S. Securities and Exchange Commission.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
-
U.S. Food and Drug Administration. (2021). Molluscum contagiosum: Unapproved products containing cantharidin. FDA.
-
U.S. Patent and Trademark Office. (2024). Patent Center and Patent Assignment data for cantharidin formulations and topical treatment technologies. USPTO.